-
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
01 Jun 2025 12:10 GMT
… , including analysis by age, race, region, … Notes
HR-positive breast cancer
Breast cancer is the second … Estrogen receptor positive breast cancers have patient specific hormone … metastatic hormone receptor‑positive breast cancer. Breast Cancer Res. 2021; 23 …
-
Suchata Chuangsri Wins Miss World 2025, Breast Cancer Warrior, 5'11 Height, Educational Deets, More
31 May 2025 19:58 GMT
… pageant. At the mere age of 22, she has … a life-changing battle with breast cancer
Opal who always dreamt … There, she held conversations with breast cancer survivors, doctors, and WHO … collection is used to fund breast cancer initiatives. Sharing the message …
-
Vepdegestrant may benefit certain patients with advanced breast cancer with ESR1 mutation
31 May 2025 19:56 GMT
… , HER2-negative advanced breast cancer with an ESR1 mutation … positive, HER2-negative advanced breast cancer compared with fulvestrant, … HER2-negative advanced breast cancer who progress after receiving … enrolled 624 adults (median age, 60 years; range, …
-
ESR1, PIK3CA, and Beyond: Precision Therapy Advances in HR+ Breast Cancer
31 May 2025 17:10 GMT
… in hormone receptor–positive breast cancer is PIK3CA. This … hormone receptor-positive metastatic breast cancer. 2025 ASCO Annual Meeting … of age with advanced ER-positive HER2 negative breast cancer ( … women with advanced breast cancer which progressed on …
-
Analysis of Serum Soluble Endoglin and s-CD105 Levels in Relation to Postoperative Recurrence and Metastasis in Breast Cancer Patients Treated with Modified Radical Mastectomy
31 May 2025 15:01 GMT
… recurrence and metastasis of breast cancer remains relatively scarce. … information such as age and BMI between … #47;metastasis in breast cancer patients undergoing modified radical … recurrence and metastasis of breast cancer. Additionally, Logistic regression …
-
Vepdegestrant Boosts Outcomes in ESR1-Mutant ER+/HER2– Advanced Breast Cancer
31 May 2025 14:40 GMT
… -positive, HER2-negative advanced breast cancer following progression on frontline endocrine … negative locally advanced or metastatic breast cancer previously treated with endocrine- … of age with ER-positive, HER2-negative advanced or metastatic breast cancer …
-
Vepdegestrant Outperforms Fulvestrant in PFS for ESR1-Mutant Advanced Breast Cancer
31 May 2025 14:40 GMT
… -positive, HER2-negative advanced breast cancer following progression on frontline endocrine … negative locally advanced or metastatic breast cancer previously treated with endocrine- … of age with ER-positive, HER2-negative advanced or metastatic breast cancer …
-
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
31 May 2025 12:30 GMT
… including age, curative … breast cancer (TNBC)
Triple-negative breast cancer is the most aggressive type of breast cancer … breast cancer. Approximately 10-15% of patients with breast cancer … are diagnosed with TNBC. While some breast cancers …
-
Lobular breast cancer: What are the symptoms of second most common form of breast cancer
31 May 2025 07:50 GMT
… lobular breast cancer?
Invasive lobular breast cancer is its own distinct type of breast cancer that … , your general health and your age a doctor will consider the …
-
Sarah Harding’s Legacy Inspires Groundbreaking Breast Cancer Trial Identifying High Breast Cancer Risk Among Younger Women and Push for Screening to Start at Age 30 Across England
31 May 2025 02:59 GMT
… than-average risk of developing breast cancer.
Dr. Howell believes … risk assessments from the age of 30.
This study … Howell, two-thirds of breast cancer patients have no family … her passing.
Breast Cancer: The Bigger Picture
Breast cancer remains the most …
About
© 1995-2025